Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

Coronavirus Vaccines As A Public Good: How Reasonable Is Reasonable?

During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.

Coronavirus COVID-19 Vaccines China

Latest From Pricing Debate

Lilly Signs US Bamlanivimab Contract, Raising Unanswered Allocation Considerations

The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.

Coronavirus COVID-19 Pricing Debate

Access And Affordability Are Key, Says New EMA Head

Ensuring patients have access to approved medicines is a key priority for Emer Cooke, the soon-to-be new head of the European Medicines Agency. Cooke says she will probably be a very different type of “captain” of the “wonderful ship” that is the EMA.

Market Access Europe

The Future Of Purdue: Will The ‘Public Benefit Corporation’ Model Take Off?

Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a public benefit company could have far-reaching significance for the industry – if it ever gets off the ground.

Pricing Debate Legal Issues

Biden, Germany And Bringing A National Drug Pricing Negotiation Process To US

Germany uses government facilitated price negotiations between publicly funded insurers and manufacturers that are based on an independent assessment of how much added value a drug provides.

Pricing Debate Elections

German Insurers Want End To Free Pricing In Amnog Review

Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.

Europe Germany

COVID-19 And The Drug Pricing Debate: Disruption Helps Industry More Than R&D

CEO accountability hearing in US House shows that the COVID-19 outbreak is helping to blunt attacks on the drug industry over its pricing – just not entirely in the way the industry hoped.

Pricing Debate Politics

Cost Offsets Crucial For Uptake Of Advanced Therapies

To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.

Market Access Policy

French To Speed Up Early Access Procedure

The French government is to implement a simplified mechanism for making new, innovative medicines available to patients more quickly before they are formally approved for marketing. The target for reimbursement spending on health care in general has been increased for 2021 and includes a special provision for coronavirus-related expenditure.

France Market Access

Pharma Catches A Break As Democrats Stumble In Rollout Of Pricing Investigation

House Oversight Committee plans to grill more companies on pricing later this year, but rushed rollout of reports from a long-running investigation, combined with competing higher profile news events, seemed to dampen the blow of the latest drug pricing scrutiny. Democrats failed to offer any new, unified solutions for their grievances with industry, while Republicans largely rushed to pharma’s defense.

Pricing Debate Policy
See All
UsernamePublicRestriction

Register